Will Participate in AAPI Conferences in Mumbai
and Orlando in 2015
Commercial Strategist Deanna Angello Appointed
to Strategic Advisory Board
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
http://www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company ("Provectus"), announced today that it
has agreed to sponsor the activities of the American Association of
Physicians of Indian Origin (AAPI). In addition, Provectus will
participate at AAPI's 2015 Global Healthcare Summit in Mumbai,
India, running from January 2-4, 2015, as well as at the Annual
AAPI Conference in Orlando, Florida, running from June 17-21,
2015.
Peter Culpepper, COO and CFO of Provectus, said, “We are very
pleased to be sponsoring AAPI in the coming year, and we believe
the relationship will benefit both AAPI and our shareholders. One
of the benefits to Provectus will be engaging the Indian market
through trusted physicians for PV-10, our novel investigational
cancer treatment. We expect this will not only assist us in gaining
regulatory approval in India but also will support our patient
recruitment efforts as we embark on our phase 3 clinical trial of
PV-10 for the treatment of melanoma.”
He continued, “AAPI is the umbrella organization representing
the interests of over 60,000 doctors of Indian origin in the USA,
and there are over 25,000 medical residents and fellows currently
in USA. This gives us tremendous reach in America as well as on the
subcontinent. One in every seven American patients is seen by an
Indian doctor, and this ratio is even higher in the smaller towns
and underserved areas due to the larger proportion of Indian
doctors in more remote locations. As a result, the Indian doctor
also serves the most diverse group of patients in the USA including
Caucasians, African Americans, Hispanics and other groups, which is
important for clinical research and trials.”
Mr. Culpepper concluded, “We will hit the ground running with
AAPI by attending their Global Healthcare Summit (GHS) in Mumbai,
India, starting January 2, 2015. At this GHS, we expect around 800
delegates to attend. Between 150 and 200 will be from the USA, and
some from the United Kingdom, Canada, Middle East and Australia. In
addition, AAPI will have a live extension to its members in the USA
who are unable to attend, as well a live telecast to an estimated
50,000 doctors around India. We will inform this huge group of
doctors from around the globe about the progress we have made with
PV-10 to date, what we are planning in the anticipated phase 3
clinical trial, and what we have learned about PV-10 for
indications other than melanoma.”
Dr. Ravi Jahagirdar, MD, President of AAPI, said, “We are very
happy to have Provectus as an official sponsor of AAPI and to enjoy
their participation at our coming meetings in Mumbai and Orlando in
2015. The Indian diaspora offers a unique, global network of
physicians who can increase the communication of medical
developments like the clinical results shown thus far for PV-10.
Moreover, we have close professional, educational and family ties
to India itself, a nation of 1 billion. We believe this
introduction of Provectus to the healthcare industry in India will
be well received, since PV-10 has many features that make it well
suited for local conditions.”
Provectus has also expanded the membership of its Strategic
Advisory Board with the addition of Deanna Angello, Director,
Commercial Strategy and New Business Planning for the Global
Established Pharma business at Pfizer Inc. In this role, she is
focused on new business opportunities for the US region, notably in
areas such as licensing of new assets, mergers and acquisitions,
and strategic partnerships. She was promoted to this position from
her role as Senior Manager, Marketing, Lyrica, a product approved
for fibomyalgia, diabetic peripheral neuropathy and other
pain-related conditions. Prior to that she was in Strategy &
Analytics, where she worked on diabetes and Alzheimer’s disease
products. Before joining Pfizer, Deanna was a management consultant
at Booz Allen and Bearing Point where her efforts concentrated on
strategic planning, organizational effectiveness and business
process improvement. Ms. Angello holds a B.S. in Psychology from
the University of Pittsburgh and a Masters in Business
Administration from the Kelley School of Business at Indiana
University. As part of her graduate studies, she studied for a
semester at St. Gallen University in Switzerland. Ms. Angello also
serves as a Board Member of the Association for Frontotemporal
Degeneration (AFTD), a national and dynamic 501(c)(3) healthcare
non-profit dedicated to raising awareness and ultimately finding a
cure for frontotemproal degeneration (FTD), a rare
neurodegenerative disease.
Dr. Craig Dees, Ph.D., CEO of Provectus, said, “We are delighted
to have Deanna join our Strategic Advisory Board. She is a highly
experienced, forward-thinking healthcare and pharmaceutical
strategist, with commercial experience in marketing and business
development and we look forward to working with her in the coming
months.”
Ms. Angello stated, “I am very pleased to be joining the
Provectus Strategic Advisory Board just as they are beginning their
phase 3 clinical trial of Intralesional PV-10 for the treatment of
melanoma. It is a very exciting time for the Company both
scientifically and commercially, and I look forward to contributing
to its success.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials can be found at the NIH registry,
www.clinicaltrials.gov. For additional information about Provectus,
please visit the Company’s website at www.pvct.com or contact
Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and
express management’s current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2013, and in our Quarterly Reports on Form 10-Q for
the quarters ended March 31, 2014, June 30, 2014, and September 30,
2014), and the following:
our determination, based on guidance from the
FDA, whether to proceed with or without a partner with a phase 3
trial of PV-10 to treat locally advanced cutaneous melanoma and the
costs associated with such a trial if it is necessary;
our determination whether to license PV-10,
our melanoma drug product candidate, and other solid tumors such as
liver cancer, if such licensure is appropriate considering the
timing and structure of such a license, or to commercialize PV-10
on our own to treat melanoma and other solid tumors such as liver
cancer;
our ability to license our dermatology drug
product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
our ability to raise additional capital if we
determine to commercialize PV-10 and/or PH-10 on our own, although
our expectation is to be acquired by a prospective pharmaceutical
or biotech concern prior to commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COOPhone: 866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon
Nurse, DM, SVP – Investor RelationsPhone: 212-564-4700orBill Gordon
– Media RelationsPhone: 212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024